No Data
Retail Investors Invested in Qyuns Therapeutics Co., Ltd. (HKG:2509) Copped the Brunt of Last Week's HK$573m Market Cap Decline
Express News | Qyuns Therapeutics - QX001S (Sailexin, Ustekinumab Injection) Drug Registration Certificate Approved and Issued by Nmpa
CSPC Pharmaceutical Group Limited-B (02509.HK): China Securities Regulatory Commission accepted the company's H股全流通计划申请.
Great Wall News October 28th, Quansin Biotech-B (02509.HK) announced that the China Securities Regulatory Commission has recently accepted the company's shareholders' suggestions to implement the application for full circulation of H shares. According to the relevant application documents, the company has applied to convert 17,322,400 shares held by certain shareholders into H shares and list them on the Hong Kong Stock Exchange, accounting for approximately 7.80% of the company's total issued share capital as of the announcement date. After the full circulation of H shares, all domestic shareholders participating in the full circulation of H shares will still need to comply with the share lock-up requirements under the Hong Kong Stock Exchange listing rules and applicable laws and regulations.
Hong Kong stock abnormal | Chang Xin Biology-B (02509) rose more than 7%, achieving revenue of 44.919 million yuan in the first half of the year. Previously reached a cooperation with huadong medicine.
China Good Biotech-B (02509) rose more than 7%, as of the time of publication, it increased by 7.54%, closing at 24.95 Hong Kong dollars.
QYUNS-B: 2024 INTERIM REPORT
Does Qyuns Therapeutics (HKG:2509) Have A Healthy Balance Sheet?
No Data
No Data